Biotechnology
CEM Corporation acquires key assets of Intavis Bioanalytical Instruments
MATTHEWS, North Carolina, Oct. 29, 2019 /PRNewswire/ -- CEM Corporation today announced that it has entered into a definitive agreement to purchase the instrumentation lines of Intavis Bioanalytical Instruments AG, with headquarters inCologne, Germany. The acquisition allows CEM to strengthen its...
2019-10-29 20:30
2413
Werum IT Solutions honored with Frost & Sullivan Customer Value Leadership Award
LONDON, Oct. 28, 2019 /PRNewswire/ -- Based on its recent analysis of the global manufacturing execution system (MES) market for pharmaceuticals, biotechnology, and cell & gene therapies, Frost & Sullivan recognizes Werum IT Solutions with the 2019 Global MES for Pharmaceuticals, Biotechnology, a...
2019-10-28 22:00
997
EW Nutrition Opens New Production Plant in China
SHANGHAI, Oct. 28, 2019 /PRNewswire/ -- On 29 October, German-based company EW Nutrition will officially open its new production plant inChina. The new plant is the next step in the successful development of EWN Biotechnology Shanghai. By offering holistic, science-backed solutions, EW Nutrition ...
2019-10-28 19:08
3283
Kazia Raises A$4.0 Million to Progress R&D Programs
SYDNEY, Oct. 28, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the completion of a placement of ten million new fully paid ordinary shares in the Company (New Shares) to institutional, profess...
2019-10-28 10:16
7206
HistoIndex Announces Global Partnerships To Expand AI-Based Digital Pathology Platform As A Drug Discovery Tool In Preclinical Studies For Nonalcoholic Steatohepatitis (NASH)
SINGAPORE, Oct. 28, 2019 /PRNewswire/ -- HistoIndex
2019-10-28 08:38
1848
WuXi STA's Jinshan Facility Passes EMA Inspection
SHANGHAI, Oct. 28, 2019 /PRNewswire/ -- STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announced today that its Jinshan manufacturing facility inShanghai, China has successfully passed an inspection by the European Medicines Agency (EMA) with no critical and no major fin...
2019-10-28 08:00
2769
Chugai Renews License to EpiVax's ISPRI In Silico Toolkit for Immunogenicity Assessment
PROVIDENCE, Rhode Island, Oct. 23, 2019 /PRNewswire/ -- Announced today, Chugai Pharmaceutical Co., Ltd. ("Chugai"), a member of the Roche Group, will extend the company's licensed access to theImmunogenicity Screening and Protein Reengineering Interface (ISPRI) toolkit developed by EpiVax, Inc. ...
2019-10-23 04:10
1651
TissueCypher® Further Validated to Accurately Risk Stratify Barrett's Esophagus Patients With Non-Dysplastic or Low-Grade Dysplasia Diagnoses: Findings Shared at Two Major GI Conferences
Data presented at ACG, UEGW illustrates the fourth independent validation of TissueCypher performance for risk stratifying non-dysplasticBarrett's esophagus (NDBE) patients; expands indication for testing low-grade dysplasia (LGD) PITTSBURGH, Oct. 23, 2019 /PRNewswire/ -- Cernostics, developer of...
2019-10-23 01:59
1287
Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma
SUZHOU, China, Oct. 21, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today ...
2019-10-21 08:00
2353
GELITA & Geltor Sign Letter of Intent to Commercialize First Animal-Free Biodesigned Collagen for Dietary Supplements, a Market with Huge Growth Potential
LAS VEGAS, Oct. 17, 2019 /PRNewswire/ -- In the halls of the SupplySide West (SSW) Expo, officials from both GELITA and Geltor signed a letter of intent for developing, producing and marketing the first ingestible animal-free collagen proteins – to be launched in late 2020. In this arrangement, G...
2019-10-17 18:32
1649
MetGen Earns Acclaim from Frost & Sullivan for its Unique, Customized Enzyme Technologies, METNIN™ and ENZINE®
The technologies solve the industry's major pain points regarding the valorization of lignin, shorter technology development cycles, and customization of enzymes for different applications LONDON, Oct. 17, 2019 /PRNewswire/ -- Based on its recent analysis of the European industrial enzymes marke...
2019-10-17 15:00
992
Curiox Biosystems Achieves Commercialisation and Fund Raising Success in North Asia with the Support of Cornerstone Investor, ZIG Ventures
* CURIOX BIOSYSTEMS, is an A*STAR spinoff company, that develops bioinstrumentation solutions used in cell analysis and therapy for the pharmaceutical and biotech industries. The company has successfully penetrated theUSA, PRC, Korean and European markets and also secured a Series B funding of ...
2019-10-16 07:00
1821
Celemics Expedites Target Enrichment NGS Data Insights by Partnering With BlueBee on a Global Genomics Data Solution
SEOUL, South Korea, and RIJSWIJK, The Netherlands, Oct. 15, 2019 /PRNewswire/ -- Celemics, provider of NGS target enrichment kits and innovative sequencing platforms, announced today the release of a comprehensive NGS target enrichment workflow for clinical and translational research applications...
2019-10-15 19:00
1745
CTFH and Insilico Medicine Enter Al Drug Discovery Collaboration Focused On Accelerating First-in-Class Therapeutics, Worth Up to $200 million
HONG KONG and NANJING, China, Oct. 9, 2019 /PRNewswire/ -- Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program AI drug discovery collaboration agreement with Jiangsu Chia Tai Fenghai Pharmaceu...
2019-10-09 20:58
1997
Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial
LONDON, MUMBAI, India and BAYREUTH, Germany, Oct. 9, 2019 /PRNewswire/ -- - RESILIENT Protocol captures Encyclopedic information from tumors and uses Artificial Intelligence (AI) to optimize treatments; - Objective Response and Disease Control Comparable to or better than most Immunotherapy opti...
2019-10-09 17:56
1391
Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer
HANGZHOU, China and SHAOXING, China, Oct. 8, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Dr.Han...
2019-10-08 08:00
2623
Cross-industrial technologies make a splash in Asia Agri-Tech Expo in Taipei
TAIPEI, Oct. 5, 2019 /PRNewswire/ -- The Asia Agri-Tech Expo & Forum 2019 will take place at Taipei Nangang Exhibition Center Hall 1 fromOctober 31 to November 2. Organised by Informa Markets of Taiwan Office (UBM Taiwan), the tradeshow features innovative, eco-friendly and sustainable manufac...
2019-10-05 10:06
3449
AGC Biologics Appoints New Site Head/General Manager of Copenhagen, Denmark Operations
Jeffrey D. Mowery Named Site Head/General Manager BOTHELL, Washington, Oct. 1, 2019 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the appointment ofJeffery D. Mowery as Site Head/General Manager of theCopenhagen,...
2019-10-01 07:00
2251
Interleukin 11 Identified as New Therapeutic Target for Idiopathic Pulmonary Fibrosis
* Idiopathic pulmonary fibrosis (IPF) is a severe and fatal disease that causes lung damage and scarring * Blocking a protein called interleukin-11 (IL11), which is abnormally high in the lungs of patients with IPF, can reverse lung fibrosis and scarring in preclinical studies * Enleofen Bi...
2019-09-30 15:00
1052
Preclincal Results of Baoyuan's Next-Generation ROS1/NTRK Inhibitor AB-106 Published in Nature Communications
HANGZHOU, China, Sept. 25, 2019 /PRNewswire/ -- The preclinical results of AB-106 (original code: DS-6051b), an investigational next generation ROS1/NTRK dual inhibitor exclusively in-licensed by AnHeart Therapeutics, a wholly-owned subsidiary of Baoyuan Biopharmaceuticals Technology (Hangzhou) C...
2019-09-25 18:44
4193
Week's Top Stories
Most Reposted
Agoda Partners with Sands China to Boost Tourism
[Picked up by 316 media titles]
2024-09-05 11:00The Beach Grill Unveils Exciting New Dishes: Elevating The Beachfront Dining Experience
[Picked up by 297 media titles]
2024-09-05 11:21
povo2.0, Japan's favourite digital telco, achieves highest user engagement and customer satisfaction rates with Circles' SaaS technology
[Picked up by 294 media titles]
2024-09-06 10:00Armacell will take complete ownership of the successful aerogel joint venture, AJA, following an agreement with JIOS Aerogel
[Picked up by 285 media titles]
2024-09-02 14:00Shiperoo Pioneers Tech-led Retail Returns and Fulfilment with AUD 30 Million Investment in Robotic Automated Facilities in Australia and New Zealand
[Picked up by 276 media titles]
2024-09-04 09:12
Most Read
Shiperoo Pioneers Tech-led Retail Returns and Fulfilment with AUD 30 Million Investment in Robotic Automated Facilities in Australia and New Zealand
2024-09-04 09:12
7610
Agoda Partners with Sands China to Boost Tourism
2024-09-05 11:00
6941
The Beach Grill Unveils Exciting New Dishes: Elevating The Beachfront Dining Experience
2024-09-05 11:21
5381
Yadea Enters Thai Market with Grand Opening of Three New Stores
2024-09-01 12:44
4394
